The nasal spray to ease intractable depression appears on the US market after decades without novel antidepressant treatments.

The treatment will be tested in a handful of patients who suffered nerve damage in sports or traffic accidents.

Two studies show signs that the introduced DNA is functioning, but it’s too early to know if patients actually benefit.

YODA, a program facilitated by Yale University researchers, has successfully distributed clinical trial records from Johnson & Johnson and Medtronic to external researchers since 2013.

Since their discovery in 2006, induced pluripotent stem cells have been poised to reprogram regenerative medicine. Twelve years on, here’s how far they’ve come.

The study will examine the efficacy of four drugs—an antiviral and three monoclonal antibodies—that are already being used to treat patients in Democratic Republic of Congo.

Two patients who received Sangamo’s zinc finger–based treatment for Hunter syndrome have lower biomarkers of the condition, but no signs of new enzyme production.

A mouse study adds to the growing body of work disputing the ability of progenitor cells to regenerate muscle tissue in adult mammals’ hearts.

The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.